Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 11/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 8/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.41 |
| ▸ | WEE1 | P30291 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4738344 | 0.82 | RIPK2 (0.52) | RIPK2NOD2ACVR1WEE1SRC | |
| SCHEMBL3533803 | 0.82 | WEE1 (0.39) | RIPK2ACVR1WEE1SRCMAPK14 | |
| SCHEMBL27781139 | 0.79 | WEE1 (0.37) | WEE1SRCMAPK14ABL1TDP2 | |
| SCHEMBL26517190 | 0.77 | RIPK2 (0.48) | RIPK2NOD2ACVR1WEE1SRC | |
| SCHEMBL31426289 | 0.76 | BRD4 (0.42) | RIPK2NOD2ACVR1WEE1SRC | |
| SCHEMBL29498198 | 0.76 | RIPK2 (0.65) | RIPK2NOD2ACVR1WEE1SRC | |
| SCHEMBL20564933 | 0.76 | RIPK2 (0.65) | RIPK2NOD2ACVR1WEE1SRC | |
| SCHEMBL4083936 | 0.75 | RIPK2 (0.65) | RIPK2NOD2ACVR1WEE1SRC | |
| SCHEMBL30837130 | 0.75 | ABL1 (0.52) | RIPK2NOD2ACVR1WEE1SRC | |
| SCHEMBL20563978 | 0.75 | ABL1 (0.52) | RIPK2NOD2ACVR1WEE1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645764-B2 | Kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101535308-A | Substituted 6-phenyl-pyrido [2,3-D] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same | HOFFMANN LA ROCHE (CH) | 2009-09-16 | — | — | CN | disclosed |
| EP-2094698-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | ROCHE PALO ALTO LLC | 2008-06-05 | — | — | US | disclosed |
| WO-2008055842-A1 | SUBSTITUTED 6-PHENYL-PYRIDO [2,3-D] PYRIMIDIN-7-ONE DERIVATIVES AS KINASE INHIBITORS AND METHODS FOR USING THE SAME | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132528-A1 | Fused pyrimido-pyridone derivatives; to treat p38 MAP kinase-mediated and Raf kinase-mediated diseases; side effects reduction; broad spectrum antiproliferative agents; N-Cyclopropyl-4-methyl-3-[8-methyl-7-oxo-2-(tetrahydro-pyran-4-ylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidin-6-yl]-benzamide | MAP3K6, MAP3K1, MAP3K2 | RIPK2 321/4885NOD2 2127/4885ACVR1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.